JOP20190201B1 - تركيبة لاستئصال الملوية البوابية - Google Patents

تركيبة لاستئصال الملوية البوابية

Info

Publication number
JOP20190201B1
JOP20190201B1 JOJO/P/2019/0201A JOP20190201A JOP20190201B1 JO P20190201 B1 JOP20190201 B1 JO P20190201B1 JO P20190201 A JOP20190201 A JO P20190201A JO P20190201 B1 JOP20190201 B1 JO P20190201B1
Authority
JO
Jordan
Prior art keywords
helicobacter pylori
formula
eradicating helicobacter
formulation
present
Prior art date
Application number
JOJO/P/2019/0201A
Other languages
English (en)
Inventor
Dongkyu Kim
Kyeongmin Oh
Yu-Gyeong Park
Haneul Jeong
Shin-Young Ryu
Geun Seog Song
Naree Shin
Hyun Ji Kang
Ahrong Kim
Eun Ji Kim
Eun Kyung Kim
Jae Min Kim
Bong Tae Kim
Ji Won Lee
Original Assignee
Hk Inno N Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hk Inno N Corp filed Critical Hk Inno N Corp
Publication of JOP20190201A1 publication Critical patent/JOP20190201A1/ar
Application granted granted Critical
Publication of JOP20190201B1 publication Critical patent/JOP20190201B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

يتعلق الاختراع الحالي بتركيبة لاستئصال الملوية البوابية واستخدامها. تحافظ تركيبة الاختراع الحالي على درجة حموضة pH داخل المعدة عند مستوى معين أو أعلى لفترة زمنية معينة أو أكثر، وبذلك تزيد من عمل الأموكسيسيلين والكلاريثروميسين إلى الحد الأقصى لإظهار تأثير ممتاز في استئصال الملوية البوابية.
JOJO/P/2019/0201A 2018-08-29 2019-08-28 تركيبة لاستئصال الملوية البوابية JOP20190201B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20180102250 2018-08-29

Publications (2)

Publication Number Publication Date
JOP20190201A1 JOP20190201A1 (ar) 2020-02-29
JOP20190201B1 true JOP20190201B1 (ar) 2024-04-18

Family

ID=69643254

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2019/0201A JOP20190201B1 (ar) 2018-08-29 2019-08-28 تركيبة لاستئصال الملوية البوابية

Country Status (25)

Country Link
US (2) US20210196685A1 (ar)
EP (1) EP3843723B1 (ar)
JP (1) JP7189327B2 (ar)
KR (1) KR20200026118A (ar)
CN (1) CN112638378A (ar)
AR (1) AR116026A1 (ar)
AU (1) AU2019328903B2 (ar)
CA (1) CA3107624C (ar)
DK (1) DK3843723T3 (ar)
EA (1) EA202190622A1 (ar)
ES (1) ES3060114T3 (ar)
FI (1) FI3843723T3 (ar)
GE (2) GEP20227431B (ar)
JO (1) JOP20190201B1 (ar)
LT (1) LT3843723T (ar)
MX (1) MX2021002278A (ar)
MY (1) MY195494A (ar)
PH (1) PH12021550385A1 (ar)
PT (1) PT3843723T (ar)
RS (1) RS67791B1 (ar)
SG (1) SG11202101920WA (ar)
SI (1) SI3843723T1 (ar)
UA (1) UA126993C2 (ar)
UY (1) UY38348A (ar)
WO (1) WO2020045992A1 (ar)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
CA3132575A1 (en) * 2019-04-18 2020-10-22 Thomas Julius Borody Compositions and methods for treating, ameliorating and preventing h. pylori infections
WO2024210689A1 (ko) * 2023-04-07 2024-10-10 제이더블유중외제약 주식회사 벤즈이미다졸 유도체의 염
TW202535382A (zh) * 2023-11-29 2025-09-16 南韓商第一藥品股份有限公司 包含ｚａｓｔａｐｒａｚａｎ或其醫藥上可接受的鹽之用於幽門螺旋桿菌根除的組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6753324B2 (en) * 1998-07-15 2004-06-22 Hassan Jomaa Phosphorous organic compounds and their use
KR101088247B1 (ko) * 2005-12-19 2011-11-30 라퀄리아 파마 인코포레이티드 크로메인 치환된 벤즈이미다졸 및 이들의 산 펌프억제제로서의 용도
CN101015694A (zh) * 2006-02-07 2007-08-15 沈阳东宇药业有限公司 一种治疗幽门螺旋杆菌感染的复方口服制剂
HUE056322T2 (hu) * 2015-06-08 2022-02-28 Hk Inno N Corp Benzimidazol-származék alkalmazásai éjszakai savvisszaáramláshoz
WO2017125912A1 (en) * 2016-01-21 2017-07-27 Dexcel Pharma Technologies Ltd. Methods for treating helicobacter infection
KR101829706B1 (ko) * 2016-09-21 2018-02-19 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 산부가염
CN108379258B (zh) * 2017-11-30 2020-02-18 中国医学科学院医药生物技术研究所 瑞香素在抗幽门螺杆菌中的应用

Also Published As

Publication number Publication date
EP3843723A1 (en) 2021-07-07
UY38348A (es) 2020-03-31
KR20200026118A (ko) 2020-03-10
SG11202101920WA (en) 2021-04-29
MX2021002278A (es) 2021-08-11
WO2020045992A1 (en) 2020-03-05
CA3107624C (en) 2023-10-03
BR112021003578A2 (pt) 2021-05-18
AU2019328903A1 (en) 2021-04-29
CN112638378A (zh) 2021-04-09
ES3060114T3 (ar) 2026-03-25
DK3843723T3 (da) 2026-02-09
GEP20227431B (en) 2022-10-25
LT3843723T (lt) 2026-03-25
EP3843723A4 (en) 2022-06-29
AU2019328903A8 (en) 2021-05-27
UA126993C2 (uk) 2023-03-01
PH12021550385A1 (en) 2021-09-20
CA3107624A1 (en) 2020-03-05
MY195494A (en) 2023-01-26
JOP20190201A1 (ar) 2020-02-29
US20250241897A1 (en) 2025-07-31
JP2021535910A (ja) 2021-12-23
AR116026A1 (es) 2021-03-25
US20210196685A1 (en) 2021-07-01
PT3843723T (pt) 2026-01-27
EP3843723B1 (en) 2026-01-07
FI3843723T3 (fi) 2026-02-12
JP7189327B2 (ja) 2022-12-13
GEAP202215593A (en) 2022-07-11
EA202190622A1 (ru) 2021-06-10
SI3843723T1 (sl) 2026-04-30
AU2019328903B2 (en) 2023-01-05
RS67791B1 (sr) 2026-03-31

Similar Documents

Publication Publication Date Title
JOP20190201B1 (ar) تركيبة لاستئصال الملوية البوابية
MA49566A (fr) Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques
LT3781561T (lt) Metilą modifikuojančių fermentų moduliatoriai, kompozicijos ir jų naudojimas
WO2019090085A8 (en) Modulators of the integrated stress pathway
JOP20210158A1 (ar) مُعَدِّلات التعبير الجيني عن hsd17b13
BR112017027147A2 (pt) agente estimulante de restauração/crescimento de cabelo
JOP20210050A1 (ar) معدلات تعبير pnpla3
HUE058662T2 (hu) Ciklikus dinukleotidok mint rákellenes szerek
MX2019007571A (es) Polimorfos.
EA201991898A1 (ru) Двойные ингибиторы magl и faah
EP3694867C0 (en) Cyclic dinucleotides as anticancer agents
MA51305A (fr) Stimulateurs de sgc
EP3756471A4 (en) ORAL INGESTION COMPOSITION
EA201892500A1 (ru) Применение фракции лигнина в качестве антифитопатогенного агента и содержащие ее антифитопатогенные композиции
EA202091471A1 (ru) Полиморфы
WO2015172040A3 (en) IMMUNOMODULATING β-1,6-D-GLUCANS
EA202090732A1 (ru) Составы для трансдермального введения
DOP2023000241A (es) Moduladores de trex1
EP3805151A4 (en) OZONE GENERATING DEVICE
EP3866916C0 (en) DEVICE FOR STIMULATING THE MEIBOMAN GLANDS
MX2021004581A (es) Composiciones acuosas que comprenden omega nitrooxi-1-alcanoles.
IL262050B (en) Compositions comprising cbd for treating hemorrhoids
DOP2023000236A (es) Moduladores de trex1
EP3765618A4 (en) PLANT EXPRESSION ENHANCER
IT201700045255A1 (it) Metodo per modulare l'assorbimento fagocitario di un principio attivo o un suo precursore da parte di macrofagi.